In Flemingsberg, we cure diseases that were previously considered incurable

Earlier this year we hosted the most meaningful ATMP event of the spring, in collaboration with Miltenyi Biotec and the Karolinska ATMP Center, Karolinska University Hospital and Karolinska Institutet. We gathered over 120 participants, all sharing a vision of creating momentum to accelerate access to ATMPs in the Nordics.

”It’s fantastic, it’s a great opportunity to learn more about what’s going on at Karolinska and for the whole ATMP environment. From the Pre GMP to the manufacturing, to then the clinical trials that they offer here, and I think that’s one of the things that are really unique about the whole Flemingsberg ATMP ecosystem” – Jonathan Clarke, Development Manager at SmartCella.

During the event we launched ATMP Flemingsberg, a platform that encapsulates all the expertise within ATMP in Flemingsberg, from research to clinical implementation.

”We have everything in Flemingsberg and you can see that because they come here from Uppsala and other parts of the world to manufacture their products and do their treatments here” – Ewa Ellis, ATMP coordinator at Karolinska University Hospital.

The seminar shed light on Pre-GMP and GMP, as well as how to advance one’s process to the next level and how Vecura can assist in scaling up. Additionally, Stefan Mielke, an expert in the field, discussed equal access and emphasized the importance of collaborative efforts to make therapies more accessible to patients. Di Yu from Elicera Therapeutics also shared their journey, which began at Vecura in Flemingsberg.

“Clinical trials are very important because they bring innovation to our patients. For those of you who don’t know what CAR-T cells are, they are like glasses for T-cells, so that they can see tumor cells.” – Stephan Mielke, Professor and Scientific Director of the Cancer Center.

Watch our film below, summarizing our successful event. Together, we can accelerate access to ATMPs in the Nordics.

Visit atmpflemingsberg.se

*ATMP (Advanced Therapy Medicinal Products) också kallade Avancerade terapiläkemedel är baserade på celler, vävnader eller gener och delas in i tre huvudkategorier: somatiska cellterapier, genterapier och vävnadstekniska produkter.

Flemingsberg Science Foundation 2024 – New Opportunities Through Partnerships

As the year comes to an end, it is time to reflect and summarize our progress. We are now concluding year three of our four-year strategic period. Are we moving in the right direction to ensure that Flemingsberg becomes the obvious choice for establishments in southern Stockholm, offering a world-class innovation environment?

Cluster Engine Flemingsberg – ERDF Project for Growth in Life Science

Flemingsberg is taking a significant step towards establishing itself as a central player in Life Science with the launch of the “Cluster Engine Life Science Flemingsberg” project. The project has been granted funding from the European Regional Development Fund and aims to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) within the life science sector in the Stockholm region. The total project budget is €10.8 million for the years 2025–2027.

BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development

As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.

Go to Top